WEDNESDAY, SEPTEMBER 18 - THURSDAY, SEPTEMBER 19
DAY 1: 12:20 - 6:30 PM | DAY 2: 7:30 AM - 4:10 PM*

TS4: Practical Phenotypic Screening
Parliament

DAY 1: WEDNESDAY

12:20 - 2:00 pm Plenary Keynote Program

2:00 - 2:45 pm Dessert Break in the Exhibit Hall with Poster Viewing

2:45 - 6:30 pm Seminar Sessions

6:30 pm Seminar Close of Day

DAY 2: THURSDAY

7:30 - 8:30 am Interactive Breakfast Breakout Discussion Groups

8:40 am - 4:10 pm Seminar Sessions

Lunch also provided.

4:10 pm Seminar Concludes

Exhibit Hall Refreshment Breaks also provided.

*Training Seminar attendees have access to Plenary Keynote Program, Interactive Breakout Discussions, and Exhibit Hall Refreshment Breaks during these times.

Instructor:

Fabien Vincent, PhD, Associate Research Fellow, Discovery Sciences, Pfizer, Inc.

About This Training Seminar:

Phenotypic drug discovery is experiencing a renaissance in the pharmaceutical industry, based on its successful track record in delivering first-in-class medicines. This approach offers the promise of delivering both novel targets and chemical matter modulating a disease phenotype of interest. Although phenotypic screening may appear at first sight to be similar to target-based screening, there are some significant differences between the two approaches. These need to be properly considered and addressed to ensure the greatest likelihood of success for phenotypic drug discovery programs. This seminar will cover a range of relevant topics with a goal of providing practical information to help prosecute such programs more effectively.

What You Will Learn:

• What is the rationale for conducting phenotypic screening?
• When does phenotypic screening provide the most value? What may be the best indications for this strategy?
• Not all phenotypic assays are created equal: what are the characteristics of the best assays?
• Which libraries should be screened and why?
• What are key considerations and strategies for phenotypic screening hit triage and validation?
• What are key considerations and strategies for target/mechanism identification and validation?
• What are key considerations and strategies for safety derisking and phenotypic program progression?

Instructor Biography:

Fabien Vincent, PhD, Associate Research Fellow, Discovery Sciences, Pfizer, Inc.

Fabien Vincent, PhD, is an Associate Research Fellow in the Hit Discovery and Lead Profiling Group at Pfizer. His laboratory provides molecular pharmacology support for the small molecule project portfolios of the Immunology & Inflammation research unit and the Centers for Therapeutic Innovation. This work includes designing hit identification strategies and screening funnels, developing assays for high throughput screening as well as additional assays to elucidate the structure activity relationship of active compounds, understand their mechanism of action and facilitate translation to preclinical models. His main research interests are centered on improving the translation of discovery research to patients and specifically include phenotypic screening and atypical molecular mechanisms of action. Fabien Vincent recently led a team of Pfizer scientists in an analysis of how best to approach phenotypic screening, and specifically how to design the optimal phenotypic assays, those which can best predict compounds and mechanisms that will be effective in patients.

Fabien Vincent received a Diplôme d’Ingénieur in organic chemistry from CPE Lyon (France) before conducting graduate research in the fields of chemical biology and enzymology in the laboratory of Pr. Harold Kohn at the University of Houston. He later became a postdoctoral fellow in chemical biology at the Genomics Institute of the Novartis Research Foundation in San Diego. He entered the field of drug discovery as both a drug discovery research project leader and molecular pharmacology-biochemistry group leader. He has authored more than 30 peer-reviewed research articles, review articles and book chapters and has been invited to present his research at more than 30 conferences and other events. He is a member of the Scientific Advisory Board of the Chemical Probes Initiative and has been a NIH study section reviewer on HTS and molecular probe identification. He was recently a guest editor for a special issue in Med. Chem. Comm. surveying progress and advances in the field of phenotypic drug discovery as well as a meeting co-organizer for the Keystone symposium Phenotypic Drug Discovery: Recent Advances and Insights from Chemical and Systems Biology in March 2019.

RECOMMENDED PREMIUM PACKAGE:

Choose 2 Short Courses and 2 Conferences/Training Seminars
September 16 Pre-Conference Short Course: SC4: How to Best Utilize 3D Cells, Spheroids and PDX Models in Oncology
September 17-18 Conference: Target Identification and Validation
September 18 Dinner Short Course: SC9: Targeted Protein Degradation Using PROTACs, Molecular Glues and More
September 18-19 Training Seminar: TS4: Practical Phenotypic Screening

What is a Training Seminar?

Each CHI Training Seminar offers 1.5 days of instruction with start and stop times for each day shown above and on the Event-at-a-Glance published in the onsite Program & Event Guide. Training Seminars will include morning and afternoon refreshment breaks, as applicable, and lunch will be provided to all registered attendees on the full day of the class.

Each person registered specifically for the Training Seminar will be provided with a hard copy handbook for the seminar in which they are registered. A limited number of additional handbooks will be available for other delegates who wish to attend the seminar, but after these have been distributed, no additional books will be available.

Though CHI encourages track hopping between conference programs, we ask that Training Seminars not be disturbed once they have begun. In the interest of maintaining the highest quality learning environment for Training Seminar attendees, and because seminars are conducted differently than conference programming, we ask that attendees commit to attending the entire program, and not engage in track hopping, as to not disturb the hands-on style instruction being offered to the other participants.